Stockreport

Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency

DIMENSION THERAPEUTICS  (DMTX) 
US:NASDAQ Investor Relations: investors.dimensiontx.com
PDF Twelve trial sites recruiting patients with OTC deficiency in the United States, United Kingdom, Spain, and Canada Initial data from the company’s Phase 1/2 study antic [Read more]